Take two 78-year-olds with the same conditions on paper — diabetes, hypertension, mild kidney disease — and the same risk score. One golfs twice a week. The other has fallen twice this year, lost fifteen pounds, and can no longer manage her own medications.
Your risk model sees them as the same patient. They are not. The difference is frailty, and it is one of the most powerful predictors of who deteriorates that most stratification quietly ignores.
1. Frailty is a different axis than disease burden
Multimorbidity counts what a patient has. Frailty measures how much reserve they have left to withstand it.
Frailty is a state of diminished physiologic reserve — the body’s reduced ability to absorb a stressor and recover. It shows up as weakness, slowed mobility, exhaustion, unintended weight loss, and low activity, and it is conceptually distinct from how many diagnoses a patient carries.
Two patients can have identical problem lists and completely different frailty. That is why disease-count and HCC-based risk scores, on their own, miss it: they measure the load, not the structure carrying the load.
2. The predictive power is large
This isn’t a soft, qualitative construct. Using a deficit-accumulation frailty index built from routine data, a study of more than 86,000 older adults found that, compared with fit patients, those with severe frailty had roughly a five-fold higher risk of death within a year, with moderate and mild frailty carrying about three-fold and two-fold higher risk respectively — and similar gradients for unplanned hospitalization and ICU admission.
Frailty stratifies outcomes steeply, and it does so on an axis your diagnosis-based model isn’t built to capture.
3. Why this is tailor-made for the models you’re now entering
The populations LEAD and high-needs strategies are built around are frailty populations first, diagnosis lists second.
The frail, the homebound, the patients repeatedly cycling through the hospital — these are exactly the high-needs populations CMS is now organizing models around. Identifying them by diagnosis code alone under-finds them, because frailty’s defining features (function, mobility, weight, cognition) rarely become clean claims fields.
An organization that adds a frailty lens to its identification finds the deteriorating patient earlier and more accurately than one relying on HCCs alone — and that earlier find is the whole game in rising-risk care.
4. You can measure it without a research budget
Frailty is more capturable than teams assume. A deficit-accumulation index can be approximated from existing claims and EHR data. Simpler tools — gait speed, grip strength, unintended weight loss, a brief functional screen at the annual wellness visit — add enormous signal for very little effort.
The barrier is almost never feasibility. It’s that frailty lives in fields most organizations don’t systematically collect, because their stratification was designed around billing data instead of clinical reality.
5. What to do with it
Layer frailty onto your existing risk stratification as a distinct variable rather than assuming your HCC score already reflects it — it usually doesn’t. Use it to separate the stable multimorbid patient from the fragile one who looks identical on a claims report. And match the intervention to the axis: a frail patient often needs fall prevention, medication simplification, functional support, and goals-of-care conversations — not another disease-management protocol.
Frailty tells you not just who is at risk, but what kind of help would actually change their trajectory.
Final Thoughts
The most important thing a risk model can tell you is who is about to fall off a cliff — and frailty is often the clearest signal that a patient is near the edge, even when their diagnosis list looks unremarkable.
As someone trained as a physician who moved into analytics and strategy, I see frailty as one of the widest gaps between what claims data captures and what clinical reality contains. Close it, and you find the patients your model has been calling stable right up until the hospitalization that proved otherwise.
If your stratification measures disease burden but not frailty, you’re treating the fragile patient and the robust one as identical — until one of them decompensates. At HealtheNomics I help organizations add a frailty lens to identification, so the patients nearest the edge are found before they go over it.
Explore the services: https://healthenomics.com/services-2/
Request a strategy conversation: https://healthenomics.com/contact-us/
Connect on LinkedIn: https://www.linkedin.com/in/muhammad-ayoub-ashraf/
Website: https://www.drayoubashraf.com
Watch on YouTube: https://www.youtube.com/@HealtheNomics
